Top Markets
Coin of the day
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Hisse Senetlerindeki Sıralama #38385
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Hisse Fiyatı
$0.02468497
Piyasa Değeri
$1.01M
Değişim (1 gün)
-12.50%
Değişim (1 yıl)
-87.34%
Ülke
AU
Ticaret Chimeric Therapeutics Limited (CHM)

Kategori

Chimeric Therapeutics Limited (CHM) için P/B oranı
2026 itibarıyla P/B oranı TTM: 0
Chimeric Therapeutics Limited şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 0'dir. 2026 yılının sonunda şirketin P/B oranı 0 idi.
Chimeric Therapeutics Limited için P/B oranı geçmişi 2026 - 2026 arası
Her yılın sonunda P/B oranı
Yıl P/B Oranı Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için P/B oranı
Şirket P/B Oranı P/B Oranı Farkı Ülke
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE